Demyelinating Disorders

The damage of the protective covering (myelin sheath) that surrounds nerve fibers in brain, optic nerves and spinal cord leads to development of demyelinating disorders. The damaged myelin sheath makes the nerve impulses slow or even stop, causing neurological problems. Demyelination causes neurological deficits, such as vision changes, weakness, altered sensation, and behavioral or cognitive problems. Demyelination can occur at any age.

Symptoms of demyelinating diseases include

Loss of vision
Numbness or tingling of  upper or lower limbs
Weakness of the arms or legs
Poor coordination/gait problem
Trouble walking
Difficulty in swallowing
Slurred speech
Deceased bowel or bladder control
Impaired memory
Mood or behavioral changes
Genetic mutations, infectious agents, autoimmune reactions, Vitamin B12 deficiency and other unknown factors results in dysmyelination.

Sub-track

  • Acute Disseminated Encephalomyelitis
  • Balo’s Disease
  • Charcot-Marie-Tooth Disease
  • Guillain-Barre Syndrome
  • HTLV-I Associated Myelopathy
  • Neuromyelitis Optica
  • Schilder’s Disease
  • Transverse Myelitis
  • Diagnosis and treatment

Market Analysis: In the forecast period of 2020 to 2027, the global market for demyelinating disorders treatments is expected to increase. The myelin sheath, a protective layer that surrounds nerve fibres in the brain, optic nerves, and spinal cord, is damaged in demyelinating illnesses. The market for demyelinating disorders therapies is divided into immunomodulators, immunosuppressants, interferons, and others based on medication class. The market for demyelinating disorders therapies is divided into two segments: oral and parenteral. he demyelinating disorders therapeutics market is divided into hospitals, homecare, specialty clinics, and others based on end users. The market for demyelinating disorders therapeutics has been divided into three categories based on distribution channels: hospital pharmacy, online pharmacy, and retail pharmacy.

+1-873-889-8976